Lund, Sweden (Press Release) – Active Biotech (NASDAQ STOCKHOLM: ACTI) to­day an­nounces that the first patient has been dosed in the phase 1b/2a clin­i­cal study of tas­quini­mod for treat­ment of re­lapsed or re­frac­tory mul­ti­ple myeloma. The study, which is planned to recruit up to 54 patients, will estab­lish a max­i­mum tol­er­ated dose of tas­quini­mod as single agent and then in­ves­ti­gate tas­quini­mod in com­bi­na­tion with a stan­dard mul­ti­ple myeloma oral regi­men of ix­az­o­mib, lena­lido­mide, and dexa­meth­a­sone (IRd). For both single agent tas­quini­mod and the com­bi­na­tion of tas­quini­mod and IRd, exploratory ex­pan­sion cohorts will be …

Lund, Sweden (Press Release) – Active Biotech (Nasdaq Stockholm: ACTI) to­day provides a status up­date in the proj­ects fol­low­ing the new direction com­mu­ni­cated in early Feb­ru­ary. This abbre­vi­ated up­date is provided as a midterm replacement of the Capital Markets Day pre­vi­ously an­nounced for May 19, which we now instead are planning to host during Q4 this year subject to the status of Covid-19. Despite the Covid-19 pandemic, most ac­­tiv­i­ties in our proj­ects have proceeded ac­cord­ing to plan and, so far, no proj­ect timelines have been sig­nif­i­cantly affected.

The Phase 1b/2 study with naptumomab …

Lund, Sweden (Press Release) – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that the Board of Directors, has approved a new direction for the com­pany. This de­ci­sion follows a detailed oppor­tu­ni­ty analysis of the com­pany’s wholly owned clin­i­cal lead assets, laquinimod and tasquinimod. Based on assess­ment of the many scientific pub­li­ca­tions and extensive pre-clinical and clin­i­cal data accumulated, an analysis of the commercial attractiveness of dif­fer­en­t clin­i­cal in­di­ca­tion oppor­tu­ni­ties to Active Biotech, as well as an ex­ternal advisory chal­lenge, new focused target in­di­ca­tions and corporate priorities have been defined.

Tasquinimod will be ad­vanced in …

Lund, Sweden (Press Release) – Active Biotech AB (Nasdaq Stockholm:ACTI) an­nounces to­day that Active Biotech has been granted Orphan Drug Desig­na­tion by the U.S. Food and Drug Admin­istra­tion (FDA) for its inves­ti­ga­tional novel agent tasquinimod, for the treat­ment of mul­ti­ple myeloma.

The FDA Orphan Drug Desig­na­tion pro­gram provides orphan status to drugs and bio­log­ics which are defined as those in­tended for the safe and ef­fec­tive treat­ment, diagnoses or prevention of rare dis­eases or disorders that effect fewer than 200,000 people in the U.S. This desig­na­tion provides for a seven year mar­ket­ing exclusivity …

Good morning, myeloma world. Welcome to a new feature here at The Myeloma Beacon: Myeloma Morning.

Starting today, you can come to The Beacon every morning of the week, and a new edition of Myeloma Morning will be waiting for you. Each edition will in­clude summaries of the latest myeloma-related re­search and myeloma-related news from the business world. We'll also make sure to keep you posted on any in­ter­est­ing conversations going on in the Beacon's myeloma discussion forum.

Our coverage of re­search devel­op­ments will focus – as it always …

Lund, Sweden (Press Release) – Active Biotech (Nasdaq Stockholm: ACTI) to­day an­nounces that a pat­ent appli­ca­tion for the treat­ment of mul­ti­ple myeloma with the com­pany's com­­pound tasquinimod, to­geth­er with an inter­na­tional search report, will be pub­lic within short on WIPO's (World Intellectual Property Organi­za­tion) web site www.wipo.int. With this appli­ca­tion (WO 2016/042112), treat­ment of mul­ti­ple myeloma with tasquinimod is poten­tially pro­tected until 2035. With the aim to ex­pand the pat­ent pro­tec­tion for tasquinimod, a pre­clin­i­cal pro­gram was per­formed and very good results were achieved in models for mul­ti­ple myeloma. The existing med­i­cal …